MRNA (Moderna) 12-1 Month Momentum % : -47.87% (As of Dec. 12, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Moderna 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-12), Moderna's 12-1 Month Momentum % is -47.87%.

The industry rank for Moderna's 12-1 Month Momentum % or its related term are showing as below:

MRNA's 12-1 Month Momentum % is ranked worse than
79.17% of 1445 companies
in the Biotechnology industry
Industry Median: -12.3 vs MRNA: -47.87

Competitive Comparison of Moderna's 12-1 Month Momentum %

For the Biotechnology subindustry, Moderna's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Moderna's 12-1 Month Momentum % falls into.

Moderna (NAS:MRNA) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moderna (NAS:MRNA) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Moderna 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Moderna's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (NAS:MRNA) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

MRNA:Peru MRNA:Mexico 1MRNA:Italy 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Executives

Shannon Thyme Klinger	officer: Chief Legal Officer	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Stephen Hoge	officer: President	C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James M Mock	officer: Chief Financial Officer	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Noubar Afeyan	director, 10 percent owner	C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Stephane Bancel	director, officer: Chief Executive Officer	320 BENT STREET, CAMBRIDGE MA 02141
Arpa Garay	officer: Chief Commercial Officer	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Juan Andres	officer: See Remarks	C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paul Burton	officer: Chief Medical Officer	200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
David W Meline	officer: Chief Financial Officer	3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Jorge M Gomez	officer: See Remarks	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Sagan	director	AKAMAI TECHNOLOGIES INC, 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Tal Zvi Zaks	officer: Chief Medical Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Lori M. Henderson	officer: General Counsel and Secretary	MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Le Goff Corinne	officer: Chief Commercial Officer	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Elizabeth G Nabel	director	BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115